CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
Since the introduction of highly active antiretroviral therapy, there has been a decline in the incidence of non-Hodgkin's lymphoma among HIV-infected individuals. We described trends in the incidence of systemic non-Hodgkin's lymphoma in the UK CHIC Study from 1996-2006 and evaluated the association between immunosuppression and development of systemic non-Hodgkin's lymphoma: 286/23,155 (1.2%) individuals developed an AIDS-defining lymphoma (258 systemic). Younger age, receipt of highly active antiretroviral therapy and later calendar year were all independently associated with a reduced risk of systemic non-Hodgkin's lymphoma. A lower latest CD4 count was strongly associated with systemic non-Hodgkin's lymphoma, in patients who had (RR per log(2)(cells/mm(3)) higher: 0.62) and had not (0.70) received highly active antiretroviral therapy. Associations with other measures of immunosuppression, including nadir CD4 count, experience and duration of severe immunosuppression, were generally weaker. Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma.
Bower
Mark
M
Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK. c.sabin@pcps.ucl.ac.uk.
Fisher
Martin
M
Hill
Teresa
T
Reeves
Iain
I
Walsh
John
J
Orkin
Chloe
C
Phillips
Andrew N
AN
Bansi
Loveleen
L
Gilson
Richard
R
Easterbrook
Philippa
P
Johnson
Margaret
M
Gazzard
Brian
B
Leen
Clifford
C
Pillay
Deenan
D
Schwenk
Achim
A
Anderson
Jane
J
Porter
Kholoud
K
Gompels
Mark
M
Sabin
Caroline A
CA